NCT06184360 is a clinical trial in Neovascular (Wet) Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT06184360?

NCT06184360 is sponsored by Novartis Pharmaceuticals.

What condition does NCT06184360 study?

NCT06184360 studies Neovascular (Wet) Age-related Macular Degeneration.

Is NCT06184360 still recruiting?

NCT06184360 is currently completed. Last updated 28 December 2023.

Last reviewed 2023-12-28 · How we verify

NCT06184360

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Completed Last updated 28 December 2023

What this trial tests

trial in Neovascular (Wet) Age-related Macular Degeneration in 2,079 participants. Completed in 16 December 2022.

Timeline

31 May 2022

Primary endpoint
30 June 2022

16 December 2022

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,079
Start date	31 May 2022
Primary completion	30 June 2022
Estimated completion	16 December 2022
Sites	1 location across United States

Conditions studied

Neovascular (Wet) Age-related Macular Degeneration — all drugs for Neovascular (Wet) Age-related Macular Degeneration →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Neovascular (Wet) Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the first brolucizumab injection (index date).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06184360 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 28 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06184360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing